Synergistic interaction between tetra-arsenic oxide and paclitaxel in human cancer cells in vitro

  • Authors:
    • Won-Heui Chung
    • Bong Hwan Sung
    • Sang-Soo Kim
    • Hyangshuk Rhim
    • Hyo-Jeong Kuh
  • View Affiliations

  • Published online on: June 1, 2009     https://doi.org/10.3892/ijo_00000298
  • Pages: 1669-1679
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Similar to arsenic trioxide (As2O3), tetra-arsenic oxide (As4O6, TAO) has shown anti-proliferative and apoptosis-inducing effects against human leukemic and solid tumor cells. In order to assess the increase in efficacy, we evaluated the combinatory interaction of TAO combined with paclitaxel, 5-FU or cisplatin and studied its mechanism of action in the cell lines of human gastric, cervix and head and neck tumors. Two agents were combined at equitoxic ratios based on the IC50 of each drug. Efficacy improvement was evaluated using a combination index and isobologram at 50% inhibition level. Apoptosis induction and expression of apoptosis-related proteins was determined and the effect on microtubule polymerization was monitored. TAO combined with paclitaxel showed synergistic interaction in all three of gastric, cervix and head and neck cancer cell lines. On the other hand, TAO when combined with 5-FU or cisplatin showed an antagonistic interaction in head and neck or cervix cancer cell lines, respectively. Simultaneous treatment with TAO with paclitaxel resulted in an increased percentage of apoptotic cells and a significant increase in PARP cleavage and caspase-3 activation in the gastric and cervix cancer cells compared to TAO alone as well as the antagonistic groups (TAO with 5-FU or cisplatin). TAO suppressed the tubulin polymerization in the presence and absence of paclitaxel in a concentration-dependent manner, suggesting mitotic catastrophe as a potential mechanism of the synergism with paclitaxel. Overall, the present study suggests that TAO may have a greater potential as an anti-cancer agent against human gastric, cervix and head and neck tumors, in combination with paclitaxel. The synergistic interaction with paclitaxel may be associated with increased apoptosis via inhibition of paclitaxel-induced tubulin polymerization. Further detailed studies of combinatory mechanisms and evaluation using in vivo models are warranted.

Related Articles

Journal Cover

June 2009
Volume 34 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chung W, Sung BH, Kim S, Rhim H and Kuh H: Synergistic interaction between tetra-arsenic oxide and paclitaxel in human cancer cells in vitro. Int J Oncol 34: 1669-1679, 2009
APA
Chung, W., Sung, B.H., Kim, S., Rhim, H., & Kuh, H. (2009). Synergistic interaction between tetra-arsenic oxide and paclitaxel in human cancer cells in vitro. International Journal of Oncology, 34, 1669-1679. https://doi.org/10.3892/ijo_00000298
MLA
Chung, W., Sung, B. H., Kim, S., Rhim, H., Kuh, H."Synergistic interaction between tetra-arsenic oxide and paclitaxel in human cancer cells in vitro". International Journal of Oncology 34.6 (2009): 1669-1679.
Chicago
Chung, W., Sung, B. H., Kim, S., Rhim, H., Kuh, H."Synergistic interaction between tetra-arsenic oxide and paclitaxel in human cancer cells in vitro". International Journal of Oncology 34, no. 6 (2009): 1669-1679. https://doi.org/10.3892/ijo_00000298